SNOA
Sonoma Pharmaceuticals IncNASDAQ
Healthcare • Drug Manufacturers - Specialty & Generic
$1.11+3.74%
Close Nov 6, 2026
- Market cap
- $4.27M
- 1 month
- -4.3%
- 3 months
- -14.0%
- 1 year
- -70.5%
- 52-week range
- $1.01$3.80
- Dividend
- No dividends on record
- Short interest
- 2.3% of float108.8K shares · settled Oct 15, 2026 · -33.9% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $21.92M
- Net income
- -$2.26M
- Free cash flow
- -$2.15M
- Book value
- $6.59M
- Total debt
- $739K
- P/E
- —
- Price / sales
- 0.2×
- Price / book
- 0.6×
- FCF yield
- -50.4%
- Net margin
- -10.3%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
Read more
It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
- Website
- sonomapharma.com
- Headquarters
- Boulder, CO, United States
- Employees
- 10
- Listed
- Jan 25, 2007
- Fiscal year ends
- March
Company profile from EODHD, stored Oct 25, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | $6.4M | +59.6% | 40.2% | -$40.0K | -$330.0K |
| Mar 2026filed Jun 16, 2026 | $5.6M | +48.1% | 39.2% | -$351.0K | -$581.0K |
| Dec 2025filed Feb 10, 2026 | $4.3M | +22.0% | 37.9% | -$678.0K | -$819.0K |
| Sep 2025filed Nov 4, 2025 | $5.6M | +56.6% | 37.8% | -$337.0K | -$534.0K |
| Jun 2025filed Aug 7, 2025 | $4.0M | +18.4% | 36.5% | -$1.1M | -$1.2M |
| Mar 2025filed Jun 17, 2025 | $3.8M | +9.2% | 40.7% | -$656.0K | -$776.0K |
| Dec 2024filed Feb 5, 2025 | $3.6M | +13.6% | 35.6% | -$1.0M | -$928.0K |
| Sep 2024filed Nov 7, 2024 | $3.6M | +31.1% | 38.0% | -$850.0K | -$610.0K |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Mar 2026filed Jun 16, 2026 | $19.5M | +36.7% | 38.0% | -$2.5M | -$3.2M |
| Mar 2025filed Jun 17, 2025 | $14.3M | +12.2% | 38.2% | -$3.7M | -$3.5M |
| Mar 2024filed Jun 17, 2024 | $12.7M | -4.0% | 37.3% | -$4.7M | -$4.8M |
| Mar 2023filed Jun 21, 2023 | $13.3M | +5.1% | 33.7% | -$4.6M | -$5.2M |
| Mar 2022filed Jul 13, 2022 | $12.6M | -32.2% | 31.6% | -$5.9M | -$5.1M |
| Mar 2021filed Jul 14, 2021 | $18.6M | +3.9% | 35.2% | -$3.4M | -$4.0M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched SNOA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
108,814 shares short
-55,691 shares (-33.9%) vs Sep 30, 2026
2.3% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
164,505 shares short
-36,987 shares (-18.4%) vs Sep 15, 2026
3.4% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
201,492 shares short
+19,179 shares (+10.5%) vs Aug 31, 2026
4.2% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
182,313 shares short
-18,735 shares (-9.3%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
201,048 shares short
+192,600 shares (+2,279.8%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
8,448 shares short
-41,336 shares (-83%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind SNOA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 20 · reverse split
Effective Aug 30, 2024
Each 20 pre-split shares become 1 post-split share.
Source: EODHD
1 for 9 · reverse split
Effective Jun 20, 2019
Each 9 pre-split shares become 1 post-split share.
Source: EODHD
1 for 5 · reverse split
Effective Jun 27, 2016
Each 5 pre-split shares become 1 post-split share.
Source: EODHD
1 for 7 · reverse split
Effective Apr 1, 2013
Each 7 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if SNOA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
0 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Aug 14, 2026
Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
14 filers reported a long position in SNOA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
99.9%
of the 110.8K shares 13-F filers reported
Moves vs Q1 2026
2 added1 trimmed
2 new · 4 unchanged · 1 not comparable
Net shares held
+27.9%
across the 7 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | $49.8K · 40.5K shares | 40.5K | New |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | $32.9K · 26.8K shares | 26.8K | +34.3% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $23.1K · 18.8K shares | 18.8K | Unchanged |
| 4 | McKinley Carter Wealth Services, Inc. | $13.8K · 11.2K shares | 11.2K | Unchanged |
| 5 | UBS Group AG | $9.6K · 7.8K shares | 7.8K | +130,033.3% |
| 6 | Global Retirement Partners, LLC | $3.1K · 2.5K shares | 2.5K | — |
| 7 | MORGAN STANLEY | $2.5K · 2K shares | 2K | -0.2% |
| 8 | OSAIC HOLDINGS, INC. | $615 · 500 shares | 500 | Unchanged |
| 9 | BARCLAYS PLC | $565 · 459 shares | 459 | New |
| 10 | BlackRock, Inc. | $139 · 113 shares | 113 | Unchanged |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inGet the Full Analysis for SNOA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.